Literature DB >> 22890727

[Rheumatic diseases with primary onset in young adults: spondyloarthritis and connective tissue diseases].

R Max1, N Blank, H M Lorenz.   

Abstract

Inflammatory rheumatic diseases can occur at any age. In young adulthood spondyloarthritis and systemic lupus erythematosus in particular present the first symptoms. General practitioners and internists are the first to be contacted by patients. They should be familiar with inflammatory back pain, HLA B27, inflammatory signs in the sacroiliac joints on imaging and extra-articular manifestations in order to transfer patients suspected of having spondyloarthritis to a rheumatologist. The same applies to skin and organ involvement, especially lupus nephritis, in patients with suspected systemic lupus erythematosus, as well as antibody screening in particular for antinuclear antibodies and anti-double stranded DNA (dsDNA) antibodies. Patients are often at the beginning of their professional and family career, therefore, early diagnosis is necessary to initiate an adequate therapy and prevent or minimize long-term damage.

Entities:  

Mesh:

Year:  2012        PMID: 22890727     DOI: 10.1007/s00108-012-3028-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  26 in total

1.  Phototesting in lupus erythematosus: a 15-year experience.

Authors:  A Kuhn; M Sonntag; D Richter-Hintz; C Oslislo; M Megahed; T Ruzicka; P Lehmann
Journal:  J Am Acad Dermatol       Date:  2001-07       Impact factor: 11.527

2.  [Early axial spondyloarthritis. Diagnostic approach and screening].

Authors:  D Poddubnyy; M Rudwaleit; J Sieper
Journal:  Z Rheumatol       Date:  2012-01       Impact factor: 1.372

3.  [Skin manifestations in lupus erythematosus: clinical aspects and therapy].

Authors:  A Kuhn; V Ruland; G Bonsmann
Journal:  Z Rheumatol       Date:  2011-04       Impact factor: 1.372

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 5.  Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.

Authors:  J Braun; X Baraliakos; J Listing; J Sieper
Journal:  Arthritis Rheum       Date:  2005-08

6.  How to diagnose axial spondyloarthritis early.

Authors:  M Rudwaleit; D van der Heijde; M A Khan; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

7.  Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis.

Authors:  Henning Christian Brandt; Inge Spiller; In-Ho Song; Janis L Vahldiek; Martin Rudwaleit; Joachim Sieper
Journal:  Ann Rheum Dis       Date:  2007-04-24       Impact factor: 19.103

8.  Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.

Authors:  J Sieper; T Klopsch; M Richter; A Kapelle; M Rudwaleit; S Schwank; E Regourd; M May
Journal:  Ann Rheum Dis       Date:  2007-07-06       Impact factor: 19.103

9.  Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

10.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.